VIVUS Inc

VIVUS — Technical Presentation (June 2010)

16 slides from VIVUS's technical presentation, Jun 29, 2010

  1. Slide 1: PHEN/TPM CR Demonstrates Significant Weight Loss in Overweight/Obese Patients: the CONQUER Trial

    Kishore M. Gadde, MD Duke University Medical Center Thomas Najarian, MD Wesley W. Day, PhD VIVUS A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients With Type 2 Diabetes Mellitus or Prediabetes:

  2. Slide 2: Author Disclosure

    Author Disclosure Past 2 years Kishore M. Gadde Research support: BMS, Forest Labs, NIDDK, Pfizer, VIVUS Stock/shareholder: Orexigen Thomas Najarian Employee of Vivus, Inc. Wesley W. Day Employee of Vivus, Inc.

  3. Slide 3: Background

    Background Phentermine (PHEN) is a sympathomimetic drug approved for short-term treatment of obesity1 Topiramate (TPM), indicated for treatment of epilepsy and prevention of migraine headache, has demonstrated weight loss, cardiometabolic benefits in clinical trials2-8 A novel low-dose, controlled-r

  4. Slide 4: CONQUER Trial Objectives

    CONQUER Trial Objectives To examine weight loss and improvement in glycemic measures in the entire sample of overweight and obese subjects with related comorbidities (type 2 diabetes mellitus [T2DM] or prediabetes [impaired fasting glucose/impaired glucose tolerance, IFG/IGT], hypertension [HTN], hy

  5. Slide 5: CONQUER Trial Methods

    CONQUER Trial Methods Design: Phase 3 RCT of 56 weeks duration Subjects: 2487 overweight or obese subjects with >2 weight-related comorbidities (T2DM or prediabetes, HTN, hypertriglyceridemia, abdominal obesity) Lifestyle modification counseling for all subjects Randomization to treatment: Placebo (

  6. Slide 6: Proportions of Subjects With Comorbidities

    Proportions of Subjects With Comorbidities HTN (or >2 antihypertensive medications) – 53% Hypertriglyceridemia (or >2 lipid-lowering medications) – 36% Abdominal obesity – 99% T2DM or prediabetes – 68% T2DM diagnosis – 16% Prediabetes (IFG/IGT) – 67% >3 comorbidities – 51%

  7. Slide 7: Glycemic Parameters at Baseline (ITT)

    Glycemic Parameters at Baseline (ITT) Measure Overall Sample Prediabetes Sample T2DM Sample Upper Quartile HbA1c (%) 5.9 6.0 6.8 6.9 Fasting glucose (mg/dL) 106.2 113.4 133.9 135.3 Fasting insulin (µIU/mL) 18.1 19.3 21.5 35.3

  8. Slide 8: Weight Loss at Week 56: Overall Sample (ITT-LOCF)

    Weight Loss at Week 56 Overall Sample (ITT-LOCF) Shown on Y-axis is change in LS means. ITT data set consisted of subjects who took >1 dose of the study drug and had >1 post-baseline assessment. *P<0.0001 vs placebo (n=979) (n=488) (n=981)

  9. Slide 9: Weight Loss at Week 56: T2DM Sample (LOCF)

    Weight Loss at Week 56 T2DM Sample (LOCF) Shown on Y-axis is change in LS means. *P<0.0001 vs placebo (n=157) (n=67) (n=164)

  10. Slide 10: Change in Glycemic Measures at Week 56: Prediabetes Sample

    Change in Glycemic Measures at Week 56 Prediabetes Sample (LOCF) Included in the analysis are subjects with baseline value and >1 post-baseline observation. Changes over time are depicted with changes in LS mean values. *P<0.0001 vs placebo; †P<0.005 vs placebo Measure Baseline Mean Change at Week 5

  11. Slide 11: Change in Glycemic Measures at Week 56: T2DM Sample

    Change in Glycemic Measures at Week 56 T2DM Sample (LOCF) Included in the analysis are subjects with baseline value and >1 post-baseline observation. Changes over time are depicted with changes in LS mean values. *P<0.05 vs placebo; †P<0.005 vs placebo At study entry, T2DM subjects were being manage

  12. Slide 12: Change in Glycemic Measures at Week 56: Upper Quartile

    Change in Glycemic Measures at Week 56 Upper Quartile (LOCF) Included in the analysis are subjects with baseline value and >1 post-baseline observation. Changes over time are depicted with changes in LS mean values. *P=0.0005 vs placebo; † P<0.0001 vs placebo; ‡ P<0.001 vs placebo; §P<0.05 vs placeb

  13. Slide 13: Net Change in Concomitant Antidiabetic Medications at Week 56

    Percentage of Subjects With Net* Change in Number of Concomitant Antidiabetic Medications at Week 56: T2DM Sample (ITT) Increased Meds Percentage of Subjects (n=157) Placebo (n=67) PHEN/TPM CR 7.5/46 (n=164) PHEN/TPM CR 15/92 *Percent increase minus percent decrease

  14. Slide 14: Treatment-Emergent Adverse Events Reported in >5% of Subjects

    Treatment-Emergent Adverse Events (AEs) Reported in >5% of CONQUER Subjects: Safety Set Adverse Event (Preferred Term) Placebo (n=993) (%) 7.5/46 (n=498) (%) 15/92 (n=994) (%) Dry mouth 2.4 13.5 20.8 Paresthesia 2.0 13.7 20.5 Constipation 5.9 15.1 17.4 Upper respiratory tract infection 12.9 12.2 13.

  15. Slide 15: CONQUER Safety Overview

    CONQUER Safety Overview Most AEs were mild/moderate in severity Treatment-emergent serious AEs in the placebo, 7.5/46, and 15/92 groups were 3.8%, 2.8%, and 4.3%, respectively Overall completion rates on study drug were 57%, 69%, and 64% for placebo, 7.5/46, and 15/92, respectively Discontinuations

  16. Slide 16: CONQUER Conclusions

    CONQUER Conclusions Both doses of PHEN/TPM CR achieved robust weight loss in overweight/obese patients 7.8% to 9.8% vs 1.2% in placebo in overall sample (ITT-LOCF) 6.8% to 8.8% vs 1.9% in placebo in T2DM sample (LOCF) Weight loss with PHEN/TPM CR was associated with clinically meaningful improvement

Vivus — Technical Presentation (June 2010) on 6ix